Creative Planning Has $502,000 Stake in Stoke Therapeutics, Inc. $STOK

Creative Planning increased its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 251.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,215 shares of the company’s stock after purchasing an additional 31,617 shares during the period. Creative Planning owned approximately 0.08% of Stoke Therapeutics worth $502,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of STOK. AlphaQuest LLC bought a new position in shares of Stoke Therapeutics in the first quarter valued at $72,000. US Bancorp DE increased its position in shares of Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after acquiring an additional 11,108 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Stoke Therapeutics in the 1st quarter worth about $92,000. Russell Investments Group Ltd. bought a new position in Stoke Therapeutics in the 1st quarter valued at about $107,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its stake in Stoke Therapeutics by 33.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock valued at $108,000 after purchasing an additional 2,384 shares during the last quarter.

Wall Street Analyst Weigh In

STOK has been the subject of several analyst reports. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. JPMorgan Chase & Co. lifted their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, November 3rd. Finally, Needham & Company LLC increased their target price on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $31.00.

Stoke Therapeutics Trading Down 0.6%

STOK stock opened at $30.87 on Friday. The stock has a market cap of $1.76 billion, a P/E ratio of 46.07 and a beta of 1.14. The stock’s fifty day simple moving average is $29.03 and its two-hundred day simple moving average is $19.83. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The business had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. As a group, analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 3,662 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $31.34, for a total transaction of $114,767.08. Following the completion of the sale, the insider owned 19,798 shares in the company, valued at $620,469.32. This trade represents a 15.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 8,548 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $31.32, for a total value of $267,723.36. Following the completion of the transaction, the director owned 62,554 shares in the company, valued at approximately $1,959,191.28. The trade was a 12.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 164,758 shares of company stock valued at $4,575,161. Company insiders own 9.50% of the company’s stock.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.